BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+0.15%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$800M
AUM Growth
+$800M
(-2.1%)
Cap. Flow
+$3.22M
Cap. Flow
% of AUM
0.4%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
STAAR Surgical
STAA
|
$2.94M |
| 2 |
Lineage Cell Therapeutics
LCTX
|
$277K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 48.39% |
| 2 | Consumer Staples | 37.34% |
| 3 | Industrials | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
STAAR Surgical
STAA
$1.36B
| $318M | 39.82% | 10,840,630 +100,000 | +0.9% | +$2.94M |
|
2
Monster Beverage
MNST
$60.9B
| $299M | 37.34% | 4,679,308 | – | – |
|
3
iShares Russell 2000 ETF
IWM
$67B
| $65.3M | 8.17% | 420,000 | – | – |
|
4
Axon Enterprise
AXON
$58.7B
| $48.8M | 6.1% | 760,062 | – | – |
|
|
5
Lineage Cell Therapeutics
LCTX
$267M
| $37.4M | 4.67% | 33,980,826 +251,835 | +0.7% | +$277K |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $20.2M | 2.52% | 8,098,267 | – | – |
|
7
Serina Therapeutics
SER
$54.5M
| $11M | 1.38% | 2,997,156 | – | – |
|